Kornimate/medical-research-clean huggingface dataset:
technical failure during colorectal endoscopic full thickness resection (eftr): the "through thick and thin" study

Conditions: Endoscopic Full Thickness Resection (EFTR); Residual /Recurrent Colorectal Lesion; Full-thickness Resection Device (FTRD); Colorectal Adenoma; Non-lifting Colorectal Lesions; Intraprocedural Complication

Summary: among advanced resection techniques, endoscopic full thickness resection (eftr) allows closure and full-thickness resection by the use of the non-exposed full thickness resection device (ftrd). the study is a retrospective analysis of technical failure occurring during colorectal full-thickness resection. full thickness resection is a safe and effective procedure for "difficult" colorectal lesions. however, technical failure can occur and to date there is no evidence about type and clinical consequences in this setting.

the study is a multicentre retrospective study involving centres with experience in advanced colorectal resections. each centre is invited to submit information about the centre and to report alle the consecutive cases corresponding to technical failure.

Eligibility criteria:
inclusion criteria: * consecutive colorectal eftr procedures with technical failure by using ovesco full thickness resection device exclusion criteria: * eftr performed by exposed techniques and/or devices different from ftrd * patients not able to give informed consent for data collection
surveillance of patients with suspected acute myocardial infarction that receive early inhospital thrombolysis with metalyse

Conditions: Myocardial Infarction

Summary: obtaining data on efficacy (e.g. complete st-segment resolution) depending on the time of treatment initiation and safety of prehospital and early hospital thrombolysis with metalyse® in a real life setting outside clinical trials.


Eligibility criteria:
inclusion criteria: * male and female patient with suspected myocardial infarction, e.g. during transportation to the hospital by ambulance. no patient younger than 18 years. * possibility of obtaining relevant information concerning indication or contraindication of thrombolysis in each patient * typical chest pain with a duration of more than 30 minutes * definite infarction signs in a 12-lead-ecg with st-elevation \> 0.1 millivolt (mv) in \> 2 leads or recent left bundle branch block with typical clinical signs * symptom onset \<= 6 hours exclusion criteria: * patients older than 75 years (exception: patients appear much younger) * low body weight * no persons under 18 * contraindications according to summary of product characteristics (spc) for metalyse
periodontitis and cardiovascular events or "pave"

Conditions: Cardiovascular Disease; Coronary Heart Disease; Myocardial Infarction; Cerebrovascular Accident

Summary: the purpose of this study is to determine if treating periodontal infections (gum problems) will lead to fewer heart problems in patients at high risk for cardiovascular disease.

there is growing evidence of a strong association between infection and atherosclerosis as well as a specific link between periodontal infection (gum problems) and heart disease. previous studies have established possible effective treatments of periodontal disease. these treatments may lead to fewer heart events in persons at high risk for cardiovascular disease. in contrast to previous heart disease studies, the primary treatment in this project is directed toward infectious agents at periodontal sites. this project is a pilot randomized clinical trial to test the feasibility of selecting and refining a periodontal infection treatment and examining the effect of that treatment on future heart events. it is a multi-center planning and pilot study involving five investigational centers at the university at buffalo (lead and overall coordinating center), university of north carolina, boston university, kaiser permanente/oregon health science university, university of maryland, and a data coordinating center at the university of north carolina. central microbiology and cytokine laboratories and a biologic specimen bank are also included. a team of cardiologists, periodontists, epidemiologists, infectious disease specialists, biostatisticians, research nurses in periodontics and cardiology, and data managers has been assembled to accomplish the research with a careful, cost-effective approach. the ultimate goal is to develop a definitive randomized clinical trial that will include about 4,000 participants from approximately 15 centers across the united states

Eligibility criteria:
eligibility: * aged 75 years or less and 50% or more blockage of at least one artery in the heart, * heart problems in the last 3 years (including previous heart attack), * previous heart bypass surgery, or previous heart angioplasty with or without a stent, and at least 6 natural teeth present in the mouth and evidence of mild to severe gum problems. exclusion: any of the following: * a major illness requiring hospitalization, * renal dialysis, * serum creatinine \> 3 mg/dl, * organ transplant recipient requiring immunosuppression medication, * surgery needed in the next 3 years, * chemotherapy in the past 3 years, * head and/or neck radiation at any time in the past, * liver dysfunction, * class iv congestive heart failure, * drug or alcohol abuse, * pacemaker or aicd/defibrillator.

Keywords: heart attacks stroke angina
the effect of surgical incision drep use in endotracheal tube fixation

Conditions: Preterm

Summary: it is aimed to minimise both unplanned extubation and skin damage with the surgical incision drep that we will use to fix the endotracheal tube in neonatal preterm infants and to reduce the complications that may develop due to these events. in addition, it is aimed to evaluate the relationship between these parameters by using devices measuring skin moisture, skin ph and neonatal skin condition assessment scale in experimental and control groups.

the aim of this study is to investigate the effectiveness of surgical incision drape usage for securing endotracheal tubes in preterm neonates. the study will be conducted using a randomized controlled design, and participants will be divided into two groups: those using the surgical drape and those not using it. the population of the study will consist of preterm infants who are hospitalised in the neonatal intensive care unit of batman training and research hospital. intubated preterm infants between 28-34 weeks will be included in the study regardless of gender difference. research data will be collected by the following methods: demographic information, neonatal skin condition rating scale (nscs), skin ph meter device and skin moisture meter device. data will be collected every 24 hours during the intubation period. the results of the study are expected to provide important theoretical and practical contributions. the effects of parameters such as skin wounds that may occur due to endotracheal tube fixation in infants, unplanned extubation rates, skin ph and skin moisture at the site of intubation fixation will be compared between the surgical incision drep and the standard group. the research data will be analysed using ibm spss 27.0 programme (statistical package for social sciences).

Eligibility criteria:
inclusion criteria: * preterm infants between 28-34 weeks of gestation hospitalized in neonatal intensive care unit, * intubated infants on invasive mechanical ventilators, * babies who were orally intubated were included in the study. exclusion criteria: * congenital skin condition, * with circulatory problems, * congenital anomalies and metabolic disorders, * small for gestational age (sga) and large for gestational age (lga), * unplanned extubation taking place, * babies intubated for less than 24 hours will be excluded from the study.

Keywords: preterm
impact of tixel treatment on symptoms and signs in patients with dry eye disease

Conditions: Dry Eye Disease (DED)

Summary: this study will examine how a standard tixel treatment versus a sham treatment for eye wrinkles affects the symptoms and signs of dry eye disease.


Eligibility criteria:
inclusion criteria: 1. mild to moderate periorbital wrinkles 2. osdi score of at least 23 3. noninvasive tear film break up time (nibut) ≤ 10 seconds 4. no other eye or skin or immune problems 5. willing and able to provide written informed consent. 6. willing to participate in all study activities and instructions. exclusion criteria: 1. pregnancy and/or breastfeeding 2. lesions in the periorbital area 3. acute severe blepharitis 4. acute conjunctivitis 5. use of eye drops within 2 hours before examination 6. other concomitant anterior eye disease 7. has undergone outdoors/sunbed tanning during the last 4 weeks 8. is unwilling to follow the tixel aftercare instructions after each of the three tixel treatments. 9. active herpes simplex or tendency for herpes simplex in the periorbital area (meaning the subject has had the condition previously). 10. current skin cancer, malignant sites and/or advanced premalignant lesions or moles in the treatment area. 11. an impaired immune system condition or use of immunosuppressive medication. 12. collagen disorders, keloid formation and/or abnormal wound healing. 13. previous invasive/ablative procedures in the areas to be treated within 3 months prior to initial treatment or plans for such treatment during the course of the tixel2 device treatment, or before complete healing of such treatments has occurred. 14. any patient who takes or has taken any medications (including via topical application), herbal treatment (oral or topic), food supplements or vitamins, which may cause fragile skin or impaired skin healing during the last 3 months. 15. any patient who has used oral isotretinoin (accutane® or roaccutan®) within 3 months prior to treatment or less. 16. any patient who has a history of bleeding coagulopathies or use of anticoagulants. 17. any patient who has tattoos or permanent makeup in the treated area. 18. any patient who has burned skin, blistered skin, irritated skin, or sensitive skin in any of the areas to be treated. 19. any patient who underwent thread lifting of the area to be treated in the last 3 months.

Keywords: dry eye disese, tixel treatment
a phase 3 study of vx-445 combination therapy in cystic fibrosis (cf) subjects heterozygous for f508del and a gating or residual function mutation (f/g and f/rf genotypes)

Conditions: Cystic Fibrosis

Summary: this study will evaluate the efficacy, safety and pharmacodynamics of elexacaftor (elx, vx-445) in triple combination (tc) with tezacaftor (tez) and ivacaftor (iva) in subjects with cystic fibrosis (cf) who are heterozygous for f508del and a gating or residual function mutation (f/g and f/rf genotypes).


Eligibility criteria:
key inclusion criteria: * subject has a confirmed diagnosis of cf and is heterozygous for f508del and either a gating or residual function mutation (f/g and f/rf genotypes) * forced expiratory volume in 1 second (fev1) value ≥40% and ≤90% of predicted mean for age, sex, and height key exclusion criteria: * clinically significant cirrhosis with or without portal hypertension * lung infection with organisms associated with a more rapid decline in pulmonary status * solid organ or hematological transplantation other protocol defined inclusion/exclusion criteria may apply
maraviroc in patients undergoing non-myeloablative allogeneic stem-cell transplantation

Conditions: Graft-versus-host Disease; Hematopoietic Stem Cell Transplantation

Summary: this study investigates the effectiveness and safety of maraviroc (an oral medication given twice daily given in addition to the standard gvhd prophylaxis) in preventing graft versus host disease (gvhd) in patients undergoing non-myeloablative allogeneic stem-cell transplantation (sct). subjects will receive maraviroc bid (in addition to standard gvhd prophylaxis) beginning after the last dose of the chemotherapy conditioning regimen until day 30 after stem-cell infusion.


Eligibility criteria:
inclusion criteria: * patients scheduled to undergo non-myeloablative allogeneic stem-cell transplantation. * meet institutional eligibility criteria for allogeneic sct. significant criteria are: * renal function: serum creatinine \ 40 ml/min/1.72m2; * hepatic function: baseline direct bilirubin, alt or ast lower than three times the upper limit of normal; * pulmonary disease: fvc or fev1 \> 40% predicted; cardiac ejection fraction \> 40%. exclusion criteria: * patients not expected to be available for follow-up in our institution for at least 100 days after the transplant * patients who are not undergoing standard non-myeloablative sct with flu/bu conditioning and tax/mtx gvhd prophylaxis * patients with uncontrolled bacterial, viral or fungal infections * patients who take strong inducers or inhibitors of the cyp450a4 * patients receiving other investigational drugs for gvhd * women who are pregnant, plan to become pregnant or are breastfeeding

Keywords: graft-versus-host disease gvhd maraviroc non-myeloablative allogeneic stem-cell transplantation hematopoietic stem cell transplantation
monosialoganglioside ganglioside in cerebral radiation necrosis

Conditions: Cerebral Radiation Necrosis

Summary: monosialoganglioside ganglioside in cerebral radiation necrosis

a prospective phase ii trial was conducted to test the efficacy of monosialoganglioside ganglioside for the treatment of cerebral radiation necrosis

Eligibility criteria:
inclusion criteria: * undergone only one course of definitive radiotherapy for histologically confirmed nasopharyngeal carcinoma years before; * at least two consecutive mri study supporting the diagnosis of cerebral radiation necrosis(crn) with an interval of 3-4 months, with the second mri showing progressive disease compared with the first mri; * progressive neurologic symptoms or signs; * mini-mental status examination(mmse) score must be ≤27; * karnofsky performance status≥70 ; * supposed to live more than 6 months. exclusion criteria: * after the second course of radiotherapy for recurrent nasopharyngeal carcinoma; * local or regional relapse,or with distant metastasis; * cerebrovascular disease; * second primary malignancy; * diabetes.
chemotherapy combined with yangzhengxiaoji capsule in patients with advanced non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: the purpose of this study is to observe quality of life and treatment side effects in patients with advanced non small cell lung cancer (nsclc) receive chemotherapy and yangzhengxiaoji capsule.


Eligibility criteria:
inclusion criteria: 1. histology and/or cytology confirmed stage ⅳ nsclc patients; 2. with at least one measurable solid tumor (recist standard version 1.1): tumor \>=10 mm in diameter on ct or mri images, or lymph node \>=15 mm in diameter on ct or mri images; 3. eastern cooperative oncology group(ecog) score 0-1, expectant survival \> 3 months; 4. age: 18-70 years; 5. normal organ function: bone marrow: neutrophils (anc) count\>=1.5×10\^9/l, platelets count\>=100×10\^9/l, hemoglobin\>=90g/l；renal function, serum creatinine\ =60 ml/min; liver function: total serum bilirubin levels \ =5 times uln; 6. for patients with brain metastases, bone metastases or pleural effusion, systemic chemotherapy is proposed after the effective local treatment to control symptoms; 7. informed consent. exclusion criteria: 1. clinically significant hepatic dysfunction: ast or alt \> 2.5 times the uln, total serum bilirubin levels \> 1.5 times the uln; clinically significant renal insufficiency: serum creatinine \> 1.5 times the uln; 2. severe heart disease: new york heart association class ⅲ-iv class of heart failure, unstable angina, myocardial infarction, coronary revascularization six months before randomization; 3. spleen resection or combined with other severe hematopoietic system diseases; 4. uncontrolled diabetes, hypertension (above 180/120mmhg), infection or severe gastrointestinal ulcers; 5. history or present with other cancer, except for non melanoma skin cancer, cervical cancer in situ and other cured cancer for at least 5 years; 6. mental illness, without legal capacity or limited capacity; 7. pregnancy, lactation or patients with pregnancy plan; 8. participated in other clinical trail in the past 1 months or participating in other trail now; 9. other unsuitable condition decided by the investigator.

Keywords: non-small cell lung cancer fact-l scale yangzhengxiaoji
intestinal microbiota and antimicrobial resistance

Conditions: Drug Resistance, Microbial

Summary: antimicrobial resistance is regarded as one of the major global public health threats, causing at least 700,000 deaths per year. it has been estimated that if the current problem of antimicrobial resistance is not effectively tackled, it would cause the death of 10 million people worldwide by 2050. multi-drug resistant pathogen is the single most important contributing factor for inappropriate antibiotics therapy, and this in turn lead to higher mortality in patients with sepsis. the slow pace of development of new classes of antimicrobial agents limits the availability of effective therapy for multi-drug resistant organisms, both currently and in the near future. it is therefore of utmost importance to look for strategies to reduce the spread and burden of antimicrobial resistance. intestinal microbiota probably played a dominant role in determining the risk of acquisition of multi-drug resistant organisms. for instance, findings from a mouse model showed that barnesiella species conferred resistance to intestinal colonization by vancomycinresistant enterococcus. such findings were subsequently confirmed in human subjects. this is a prospective longitudinal observational study evaluating the correlation between changes in intestinal microbiota and acquisition of antimicrobial resistance in patients hospitalized for stroke. adult patients admitted to the medical unit of the prince of wales hospital with a diagnosis of acute stroke will be screened for eligibility and will be invited to participate in this study. data collected from this study will determine the correlation between antibiotics use and changes in intestinal microbiota in a cohort of hospitalized patients as well as the correlation between intestinal microbiota and acquisition of intestinal colonization or infection caused by resistant pathogens.


Eligibility criteria:
inclusion criteria: * adults aged 18 years or above, and * radiological evidence of acute ischaemic or hemorrhagic stroke * within two days of hospital admission exclusion criteria: * use of antibiotics within 4 weeks prior to the time of screening * underlying gastrointestinal diseases, including gastrointestinal malignancy, inflammatory bowel disease, resection of small or large bowel * pregnancy

Keywords: stroke intestinal microbiota antimicrobial resistance
laparoscopic cholecystectomy in management of acc within versus after 3 days

Conditions: Acute Calculous Cholecystitis

Summary: this study was aimed to assess the outcome of laparoscopic cholecystectomy in acute calculous cholecystitis in terms of conversion rates, postoperative complications and length of hospital stay within and after 3 days of symptoms onset.

the study aims to evaluate the safety and competency of laparoscopic cholecystectomy as surgical management of acute calculous cholecystitis within and after 72h of symptom onset. this study included 62 patients with acute calculous cholecystitis. patients are divided into 2 study groups by the time of laparoscopic cholecystectomy comparing to the onset of symptoms and categorized as group a \& b. immediate laparoscopic cholecystectomy is performed in group a. while late laparoscopic cholecystectomy is performed in group b. patients in both groups monitored since admission, during operations, and along the postoperative period.

Eligibility criteria:
inclusion criteria: 1. abdominal pain characteristic of acute cholecystitis, positive murphy's sign, total leucocyte count \> 10,000/ ul, and (4) ultra-sonographic evidence of acute calculous cholecystitis. 2. initial surgical management planned for immediate laparoscopic cholecystectomy. 3. patients who are fit for laparoscopy and general anesthesia. 4. patient who agree to provide short term outcome data and agree to provide contact information. exclusion criteria: 1. patients with ultra-sonographic findings of common bile duct calculi, pancreatitis, gall bladder perforation, gall bladder gangrene or gall bladder abscess. 2. patients with other associated abdominal pathology. 3. patients with any previous abdominal surgery or any significant systemic disease. 4. septic shock. 5. pregnancy/ breast-feeding mothers. 6. participation in an additional drug or device study and inability to offer informed consent.

Keywords: acute calculous cholecystitis laparoscopic cholecystectomy early laparoscopic cholecystectomy late laparoscopic cholecystectomy
mucins and toll-like receptors in asthma

Conditions: Asthma; Inflammation

Summary: this study raises two main hypotheses: 1) asthmatics patients who present with bronchial hypersecretion differ phenotypically from asthmatic patients without hypersecretion and 2) mucins in asthmatic patients with hypersecretion of bronchial mucus and the expression of tlrs differ from non-mucus hypersecretory asthmatics patients.

asthma with bronchial hypersecretion is a type of asthma poorly studied. its pathogenesis is not well understood but probably is related to the innate impaired immunity, particularly with "toll-like receptors" (tlr) and secretory mucin (muc). objectives 1) define the clinical and inflammatory phenotype of asthma with bronchial hypersecretion of mucus. 2) compare the type of mucin present in induced sputum (is) of patients with and without bronchial hypersecretion. 3) determine the expression of tlrs in the is and in the peripheral blood of asthmatics with and without bronchial hypersecretion. method: cross-sectional study which included 43 asthmatic patients, 19 with and 24 without bronchial hypersecretion. all patients underwent the following: is, spirometry, fractional exhaled nitric oxide (feno), prick test, total ige and blood albumin. analysis of mucins (muc2, muc5ac, muc5b and muc1) was determined by elisa and expression of tlr2 and tlr4 by flow cytometry. the level of asthma control was determined by the asthma control test questionnaire (act) and quality of life was assessed by the miniaqlq questionnaire.

Eligibility criteria:
inclusion criteria: * non-smokers, asthma diagnosed as per the global initiative for asthma (gina) criteria on maintenance treatment for asthma, aged 18 to 80 years. exclusion criteria: * patients were excluded from the study if they had a respiratory tract infection and/or required the use of oral corticosteroids within 30 days prior to inclusion; if they had a concomitant disease (sarcoidosis, lung cancer, pulmonary tuberculosis, bronchiectasis, nephropathy, rheumatic or liver disease); significant comorbidity that could affect the study results in the physician's judgment; or a cognitive impairment that could limit their comprehension of the subject under study or their ability to participate